GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (FRA:2Q5) » Definitions » Stock Based Compensation

Renovaro (FRA:2Q5) Stock Based Compensation : €4.11 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Renovaro Stock Based Compensation?

Renovaro's Stock Based Compensation for the three months ended in Mar. 2024 was €1.71 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was €4.11 Mil.


Renovaro Stock Based Compensation Historical Data

The historical data trend for Renovaro's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Stock Based Compensation Chart

Renovaro Annual Data
Trend Mar13 Dec14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.91 0.92 1.20 5.19 3.27

Renovaro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 0.56 0.92 0.92 1.71

Renovaro Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.11 Mil.


Renovaro Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Renovaro's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovaro (FRA:2Q5) Business Description

Traded in Other Exchanges
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.

Renovaro (FRA:2Q5) Headlines

No Headlines